Medical Tidbits,Treatment Response to ImmunoGen’s Mirvetuximab Soravtansine Found to be Substantially Greater in Ovarian Cancer with High Expression of Folate Receptor Alpha

jobs in the medical field

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported findings with mirvetuximab soravtansine, its novel folate receptor alpha (FRα)-targeting ADC product candidate, being presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (abstract #C47). Analysis of the association between the amount of FRα present on patient cancer cells and response to treatment with mirvetuximab soravtansine found nine of ten (90%) patients with high levels of FRα had an objective response on treatment.

Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015 First Chronic Dosing Trial of Oral Omecamtiv Mecarbil Showed Statistically Significant Improvements iSeveral Pre-Specified Measures of Cardiac Function and Volumes

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 8, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Cytokinetics Incorporated (NASDAQ: CYTK) today announced the presentation of data from the expansion phase of COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, in a Late-Breaking Clinical Trial session at the American Heart Association (AHA) Scientific Sessions 2015 in Orlando, Fla. read more

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

INDIANAPOLIS, Nov. 7, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monotherapy in helping patients achieve clinical remission. Findings will be shared at the American College of Rheumatology /Association of Rheumatology Health Professionals annual meeting in San Francisco, revealing superiority for investigational therapy baricitinib over methotrexate in improving multiple measures of the signs and symptoms of rheumatoid arthritis. read more

Patients Show Significant Improvement in Signs and Symptoms of Psoriatic Arthritis, Less Progression of Structural Joint Damage When Treated with Ixekizumab for 24 Weeks

/PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements in signs and symptoms of their disease when compared to placebo, while also experiencing significantly less progression of radiographic structural joint damage, reduced disability when performing certain physical functions and improved skin clearance of plaque psoriasis. read more

Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma (PTCL)

Onxeo S.A. (Paris:ONXEO: (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced the initial results from its Phase 1 trial of belinostat, its potent, pan-HDAC (histone deacetylase) inhibitor, in combination with CHOP chemotherapy regimen as first-line treatment in patients with peripheral T-cell lymphoma (PTCL). The Bel-CHOP combination has demonstrated to be well-tolerated with all components of belinostat and CHOP given at their approved therapeutic doses. Furthermore, the efficacy data indicate that the combination is a promising new regimen in PTCL that Onxeo together with its partner Spectrum Pharmaceuticals will further evaluate in a Phase 3 randomized trial, planned to begin in 2016. read more

Ignyta Announces Acquisition of Exclusive Rights to Taladegib Oncology Program from Lilly

SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX) (“Ignyta”), a precision oncology biotechnology company, today announced the exclusive license of worldwide rights relating to Eli Lilly and Company’s taladegib oncology development program in exchange for an upfront payment of $2.0 million in cash and the issuance to Lilly of approximately 1.2 million shares of Ignyta’s common stock. read more

Subscribe today for leading medical news and career advice from top medical recruiters!

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.